Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 1,411–1,420 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 1411
- Medicine slug
- sodium-ferric-gluconate-complex
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
1 hour
- Numeric value
- 1
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b25b34ab-9cf1-4a2b-bdf2-5eaf66625999 (opens source in a new tab)
Sodium Ferric Gluconate Complex label
Version not recorded · Effective date not recorded
The terminal elimination half-life for drug bound iron was approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1fe028ff-42ac-4329-b1a5-a9dadfcb79f6 (opens source in a new tab)
Sodium Ferric Gluconate Complex label
Version not recorded · Effective date not recorded
The terminal elimination half-life for drug bound iron was approximately 1 hour.
Projected row 1412
- Medicine slug
- sodium-nitroprusside
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 16
- Source count
- 14
- Agreement rate
- 1
- Recorded readings
3 days
- Numeric value
- Not parsed
- Unit
- Not recorded
- Source records
- 14
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 14 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2122b9c1-0af4-493b-82cc-63eee02f987f (opens source in a new tab)
Sodium Nitroprusside label
Version not recorded · Effective date not recorded
Clearance of SCN - is primarily renal, with a half-life of about 3 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:820eadcb-1230-4b17-a652-e69b52b3c12f (opens source in a new tab)
Sodium Nitroprusside label
Version not recorded · Effective date not recorded
Clearance of SCN¯ is primarily renal, with a half-life of about 3 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:41e11afb-5fa4-4212-889d-1092dbd0702a (opens source in a new tab)
Sodium Nitroprusside label
Version not recorded · Effective date not recorded
Clearance of SCNˉ is primarily renal, with a half-life of about 3 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d3f1276a-5944-48e3-8ff1-19995ffb7ef9 (opens source in a new tab)
Sodium Nitroprusside label
Version not recorded · Effective date not recorded
Clearance of SCN¯ is primarily renal, with a half-life of about 3 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:01841345-bed3-458f-8e99-911fbd286512 (opens source in a new tab)
Sodium Nitroprusside label
Version not recorded · Effective date not recorded
Clearance of SCN – is primarily renal, with a half-life of about 3 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5a599880-c133-44ef-a9f2-bd1b681563be (opens source in a new tab)
Sodium Nitroprusside label
Version not recorded · Effective date not recorded
Clearance of SCN¯ is primarily renal, with a half-life of about 3 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:01dfae56-3d9b-448a-84a7-03a54a533eb1 (opens source in a new tab)
Sodium Nitroprusside label
Version not recorded · Effective date not recorded
Clearance of SCN – is primarily renal, with a half-life of about 3 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a8c5d04b-c6cb-46e6-b90c-e858a0a52406 (opens source in a new tab)
Sodium Nitroprusside label
Version not recorded · Effective date not recorded
Clearance of SCN – is primarily renal, with a half-life of about 3 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a8999285-16b1-473d-8e92-684f581534f6 (opens source in a new tab)
Sodium Nitroprusside label
Version not recorded · Effective date not recorded
Clearance of SCN – is primarily renal, with a half-life of about 3 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2fa687a2-10e7-45ae-953a-9d63564c2908 (opens source in a new tab)
Sodium Nitroprusside label
Version not recorded · Effective date not recorded
Clearance of SCN - is primarily renal, with a half-life of about 3 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1f875445-f8e4-b097-e063-6294a90ad544 (opens source in a new tab)
Sodium Nitroprusside label
Version not recorded · Effective date not recorded
Clearance of SCN – is primarily renal, with a half-life of about 3 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5a689f89-3cbd-f9fa-13cc-26063feb9c83 (opens source in a new tab)
Sodium Nitroprusside label
Version not recorded · Effective date not recorded
Clearance of SCN – is primarily renal, with a half-life of about 3 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a3b83d0e-b8f7-5e90-c363-1edfcd27a33d (opens source in a new tab)
Sodium Nitroprusside label
Version not recorded · Effective date not recorded
Clearance of SCN – is primarily renal, with a half-life of about 3 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6fbfb86c-da8d-4741-b1e0-7000e2bbad5f (opens source in a new tab)
Sodium Nitroprusside label
Version not recorded · Effective date not recorded
Clearance of SCN – is primarily renal, with a half-life of about 3 days.
Projected row 1413
- Medicine slug
- solifenacin
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 34
- Source count
- 34
- Agreement rate
- 1
- Recorded readings
90%
- Numeric value
- 90
- Unit
- %
- Source records
- 34
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 34 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9558ed7a-e942-4261-8aea-6033352f79b8 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
The absolute bioavailability of solifenacin is approximately 90%, with plasma concentrations of solifenacin proportional to the dose administered.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7eb1a5d6-4972-44f4-8ab9-80b932bf81e0 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
The absolute bioavailability of solifenacin is approximately 90%, with plasma concentrations of solifenacin proportional to the dose administered.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:98b99a4c-201d-46ee-b78c-7634a64d3a8d (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
The absolute bioavailability of solifenacin is approximately 90%, with plasma concentrations of solifenacin proportional to the dose administered.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:70fece2c-a59f-43f9-abbf-ac67500e90bb (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
The absolute bioavailability of solifenacin is approximately 90%, with plasma concentrations of solifenacin proportional to the dose administered.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dadb9462-953e-4319-b9f8-5b7255d1cf9c (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
The absolute bioavailability of solifenacin is approximately 90%, with plasma concentrations of solifenacin proportional to the dose administered.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f0b8f111-1d76-4b04-9e2f-9fca9e5a0b00 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
The absolute bioavailability of solifenacin is approximately 90%, with plasma concentrations of solifenacin proportional to the dose administered.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9acee910-cdb2-4052-b8b3-c26aff1c8716 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
The absolute bioavailability of solifenacin is approximately 90%, with plasma concentrations of solifenacin proportional to the dose administered.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56026679-4002-a6c6-e063-6294a90a7b55 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
The absolute bioavailability of solifenacin is approximately 90%, with plasma concentrations of solifenacin proportional to the dose administered.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a6f154d9-7463-4b80-b80e-c06a06e36141 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
The absolute bioavailability of solifenacin is approximately 90%, with plasma concentrations of solifenacin proportional to the dose administered.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6479d24f-373e-4c9e-abaf-349f90a2bbb1 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
The absolute bioavailability of solifenacin is approximately 90%, with plasma concentrations of solifenacin proportional to the dose administered.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:48f82298-6600-4c69-a638-8dae15083fd9 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
The absolute bioavailability of solifenacin is approximately 90%, with plasma concentrations of solifenacin proportional to the dose administered.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3788df43-42dd-4778-8289-e32b5844358e (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
The absolute bioavailability of solifenacin is approximately 90%, with plasma concentrations of solifenacin proportional to the dose administered.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d96b386-febf-a510-a896-033e832c8f30 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
The absolute bioavailability of solifenacin is approximately 90%, with plasma concentrations of solifenacin proportional to the dose administered.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b0a0651e-1488-36b7-e053-2995a90a3f14 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
The absolute bioavailability of solifenacin is approximately 90%, and plasma concentrations of solifenacin are proportional to the dose administered.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:02e2aa54-1ed8-445a-a082-ac2c64b339fe (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
The absolute bioavailability of solifenacin is approximately 90%, with plasma concentrations of solifenacin proportional to the dose administered.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e04812c2-2ff7-4dff-9122-518c18f4935e (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
The absolute bioavailability of solifenacin is approximately 90%, with plasma concentrations of solifenacin proportional to the dose administered.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aea71cde-6d62-4f8d-b813-47064cb213d9 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
The absolute bioavailability of solifenacin is approximately 90%, and plasma concentrations of solifenacin are proportional to the dose administered.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92b37f2d-b1cf-49e6-a13b-0ead92c0604c (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
The absolute bioavailability of solifenacin is approximately 90%, with plasma concentrations of solifenacin proportional to the dose administered.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:663d992d-23cc-4a8e-acd5-a4bea505ba3a (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
The absolute bioavailability of solifenacin is approximately 90%, with plasma concentrations of solifenacin proportional to the dose administered.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49346a96-3d96-4702-b96e-94e635510dba (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
The absolute bioavailability of solifenacin is approximately 90%, with plasma concentrations of solifenacin proportional to the dose administered.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8ab4f222-018f-40fc-a6aa-39dab563a8a0 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
The absolute bioavailability of solifenacin is approximately 90%, with plasma concentrations of solifenacin proportional to the dose administered.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51ff19b4-09ac-4796-8869-671ddd62c578 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
The absolute bioavailability of solifenacin is approximately 90%, with plasma concentrations of solifenacin proportional to the dose administered.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b20003a6-f781-4563-9824-3e8b97c763c6 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
The absolute bioavailability of solifenacin is approximately 90%, with plasma concentrations of solifenacin proportional to the dose administered.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c84682ca-afca-a066-e053-2995a90a3257 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
The absolute bioavailability of solifenacin is approximately 90%, with plasma concentrations of solifenacin proportional to the dose administered.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:010c0657-c907-477f-8bd7-5d455a5f50eb (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
The absolute bioavailability of solifenacin is approximately 90%, with plasma concentrations of solifenacin proportional to the dose administered.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d6525817-bea1-4a4c-bed4-4873ee202cc8 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
The absolute bioavailability of solifenacin is approximately 90%, with plasma concentrations of solifenacin proportional to the dose administered.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d65dcb9-aa67-4cfb-9d15-43d0de327bd7 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
The absolute bioavailability of solifenacin is approximately 90%, with plasma concentrations of solifenacin proportional to the dose administered.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2462e9a4-66a7-4340-9a81-617f3417b495 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
The absolute bioavailability of solifenacin is approximately 90%, with plasma concentrations of solifenacin proportional to the dose administered.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d8e8f6f-0a59-479f-8415-c5c5f19e1977 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
The absolute bioavailability of solifenacin is approximately 90%, with plasma concentrations of solifenacin proportional to the dose administered.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d155c739-6870-4938-ba91-8c1b4b90afe4 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
The absolute bioavailability of solifenacin is approximately 90%, with plasma concentrations of solifenacin proportional to the dose administered.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c67107f4-348b-4a23-a67c-26fd8241ebd6 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
The absolute bioavailability of solifenacin is approximately 90%, and plasma concentrations of solifenacin are proportional to the dose administered.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:97d8a21e-4618-460f-8cf5-97a9d946039e (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
The absolute bioavailability of solifenacin is approximately 90%, with plasma concentrations of solifenacin proportional to the dose administered.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2dfc5d69-8f35-4f57-90b7-46a5f0f0febe (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
The absolute bioavailability of solifenacin is approximately 90%, with plasma concentrations of solifenacin proportional to the dose administered.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fbd6e753-1ed2-418a-8667-c674b215eabb (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
The absolute bioavailability of solifenacin is approximately 90%, with plasma concentrations of solifenacin proportional to the dose administered.
Projected row 1414
- Medicine slug
- solifenacin
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 34
- Source count
- 34
- Agreement rate
- 0.970588
- Recorded readings
45 to 68 hours
- Numeric value
- 45
- Unit
- hours
- Source records
- 33
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 33 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7eb1a5d6-4972-44f4-8ab9-80b932bf81e0 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Elimination The elimination half-life (t 1/2 ) of solifenacin following chronic dosing is approximately 45 to 68 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:98b99a4c-201d-46ee-b78c-7634a64d3a8d (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Elimination The elimination half-life (t 1/2 ) of solifenacin following chronic dosing is approximately 45-68 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:70fece2c-a59f-43f9-abbf-ac67500e90bb (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Elimination The elimination half-life (t 1/2 ) of solifenacin following chronic dosing is approximately 45-68 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dadb9462-953e-4319-b9f8-5b7255d1cf9c (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Elimination The elimination half-life (t 1/2 ) of solifenacin following chronic dosing is approximately 45-68 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f0b8f111-1d76-4b04-9e2f-9fca9e5a0b00 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Elimination The elimination half-life (t 1/2 ) of solifenacin following chronic dosing is approximately 45-68 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9acee910-cdb2-4052-b8b3-c26aff1c8716 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Elimination The elimination half-life (t 1/2 ) of solifenacin following chronic dosing is approximately 45-68 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56026679-4002-a6c6-e063-6294a90a7b55 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Elimination The elimination half-life (t 1/2 ) of solifenacin following chronic dosing is approximately 45-68 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a6f154d9-7463-4b80-b80e-c06a06e36141 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Elimination The elimination half-life (t 1/2 ) of solifenacin following chronic dosing is approximately 45 to 68 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6479d24f-373e-4c9e-abaf-349f90a2bbb1 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Elimination The elimination half-life (t 1/2 ) of solifenacin following chronic dosing is approximately 45 to 68 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:48f82298-6600-4c69-a638-8dae15083fd9 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Elimination The elimination half-life (t1/2) of solifenacin following chronic dosing is approximately 45 to 68 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3788df43-42dd-4778-8289-e32b5844358e (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Elimination The elimination half-life (t 1/2 ) of solifenacin following chronic dosing is approximately 45-68 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d96b386-febf-a510-a896-033e832c8f30 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Elimination The elimination half-life (t 1/2 ) of solifenacin following chronic dosing is approximately 45-68 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b0a0651e-1488-36b7-e053-2995a90a3f14 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
The elimination half-life of solifenacin following chronic dosing is approximately 45-68 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:02e2aa54-1ed8-445a-a082-ac2c64b339fe (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Elimination The elimination half-life (t1/2) of solifenacin following chronic dosing is approximately 45 to 68 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e04812c2-2ff7-4dff-9122-518c18f4935e (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Elimination The elimination half-life (t 1/2 ) of solifenacin following chronic dosing is approximately 45-68 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aea71cde-6d62-4f8d-b813-47064cb213d9 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
The elimination half-life of solifenacin following chronic dosing is approximately 45 to 68 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92b37f2d-b1cf-49e6-a13b-0ead92c0604c (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Elimination The elimination half-life (t 1/2 ) of solifenacin following chronic dosing is approximately 45 to 68 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:663d992d-23cc-4a8e-acd5-a4bea505ba3a (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Elimination The elimination half-life (t 1/2 ) of solifenacin following chronic dosing is approximately 45-68 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49346a96-3d96-4702-b96e-94e635510dba (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Elimination The elimination half-life (t 1/2 ) of solifenacin following chronic dosing is approximately 45 to 68 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8ab4f222-018f-40fc-a6aa-39dab563a8a0 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Elimination The elimination half-life (t 1/2 ) of solifenacin following chronic dosing is approximately 45-68 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51ff19b4-09ac-4796-8869-671ddd62c578 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Elimination The elimination half-life (t 1/2 ) of solifenacin following chronic dosing is approximately 45-68 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b20003a6-f781-4563-9824-3e8b97c763c6 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Elimination The elimination half-life (t1/2) of solifenacin following chronic dosing is approximately 45 to 68 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c84682ca-afca-a066-e053-2995a90a3257 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Elimination The elimination half-life (t 1/2 ) of solifenacin following chronic dosing is approximately 45 to 68 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:010c0657-c907-477f-8bd7-5d455a5f50eb (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Elimination The elimination half-life (t 1/2 ) of solifenacin following chronic dosing is approximately 45 to 68 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d6525817-bea1-4a4c-bed4-4873ee202cc8 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Elimination The elimination half-life (t 1/2 ) of solifenacin following chronic dosing is approximately 45-68 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d65dcb9-aa67-4cfb-9d15-43d0de327bd7 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Elimination The elimination half-life (t 1/2 ) of solifenacin following chronic dosing is approximately 45-68 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2462e9a4-66a7-4340-9a81-617f3417b495 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Elimination The elimination half-life (t 1/2 ) of solifenacin following chronic dosing is approximately 45-68 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d8e8f6f-0a59-479f-8415-c5c5f19e1977 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Elimination The elimination half-life (t 1/2 ) of solifenacin following chronic dosing is approximately 45-68 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d155c739-6870-4938-ba91-8c1b4b90afe4 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Elimination The elimination half-life (t 1/2 ) of solifenacin following chronic dosing is approximately 45-68 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c67107f4-348b-4a23-a67c-26fd8241ebd6 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
The elimination half-life of solifenacin following chronic dosing is approximately 45-68 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:97d8a21e-4618-460f-8cf5-97a9d946039e (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Elimination The elimination half-life (t 1/2 ) of solifenacin following chronic dosing is approximately 45-68 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2dfc5d69-8f35-4f57-90b7-46a5f0f0febe (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Elimination The elimination half-life (t 1/2 ) of solifenacin following chronic dosing is approximately 45-68 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fbd6e753-1ed2-418a-8667-c674b215eabb (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Elimination The elimination half-life (t1/2) of solifenacin following chronic dosing is approximately 45-68 hours.
45 hours
- Numeric value
- 45
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9558ed7a-e942-4261-8aea-6033352f79b8 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Elimination The elimination half-life (t 1/2 ) of solifenacin following chronic dosing is approximately 45 hours to 68 hours.
Projected row 1415
- Medicine slug
- solifenacin
- Compared field
- tMax
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 34
- Source count
- 31
- Agreement rate
- 0.967742
- Recorded readings
3 to 8 hours
- Numeric value
- 3
- Unit
- hours
- Source records
- 30
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 30 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7eb1a5d6-4972-44f4-8ab9-80b932bf81e0 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption After oral administration of solifenacin succinate in healthy volunteers, peak plasma concentrations (C max ) of solifenacin were reached within 3 to 8 hours after administration and, at steady-state, ranged from 32.3 ng/mL to 62.9 ng/mL for the 5 mg and 10 mg solifenacin succinate tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:98b99a4c-201d-46ee-b78c-7634a64d3a8d (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption After oral administration of solifenacin succinate in healthy volunteers, peak plasma concentrations (C max ) of solifenacin were reached within 3 to 8 hours after administration and, at steady-state, ranged from 32.3 to 62.9 ng/mL for the 5 and 10 mg solifenacin succinate tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:70fece2c-a59f-43f9-abbf-ac67500e90bb (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption After oral administration of Solifenacin Succinate Tablets in healthy volunteers, peak plasma concentrations (C max ) of solifenacin were reached within 3 to 8 hours after administration and, at steady-state, ranged from 32.3 to 62.9 ng/mL for the 5 and 10 mg Solifenacin Succinate Tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dadb9462-953e-4319-b9f8-5b7255d1cf9c (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption After oral administration of solifenacin succinate in healthy volunteers, peak plasma concentrations (C max ) of solifenacin were reached within 3 to 8 hours after administration and, at steady-state, ranged from 32.3 to 62.9 ng/mL for the 5 and 10 mg solifenacin succinate tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f0b8f111-1d76-4b04-9e2f-9fca9e5a0b00 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption After oral administration of solifenacin succinate in healthy volunteers, peak plasma concentrations (C max ) of solifenacin were reached within 3 to 8 hours after administration and, at steady-state, ranged from 32.3 to 62.9 ng/mL for the 5 and 10 mg solifenacin succinate tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9acee910-cdb2-4052-b8b3-c26aff1c8716 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption After oral administration of VESIcare in healthy volunteers, peak plasma concentrations (C max ) of solifenacin were reached within 3 to 8 hours after administration and, at steady-state, ranged from 32.3 to 62.9 ng/mL for the 5 and 10 mg VESIcare tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56026679-4002-a6c6-e063-6294a90a7b55 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption After oral administration of solifenacin succinate in healthy volunteers, peak plasma concentrations (C max ) of solifenacin were reached within 3 to 8 hours after administration and, at steady-state, ranged from 32.3 to 62.9 ng/mL for the 5 and 10 mg solifenacin succinate tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a6f154d9-7463-4b80-b80e-c06a06e36141 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption After oral administration of solifenacin succinate in healthy volunteers, peak plasma concentrations (C max ) of solifenacin were reached within 3 to 8 hours after administration and, at steady-state, ranged from 32.3 ng/mL to 62.9 ng/mL for the 5 mg and 10 mg solifenacin succinate tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6479d24f-373e-4c9e-abaf-349f90a2bbb1 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption After oral administration of solifenacin succinate in healthy volunteers, peak plasma concentrations (C max ) of solifenacin were reached within 3 to 8 hours after administration and, at steady-state, ranged from 32.3 to 62.9 ng/mL for the 5 and 10 mg solifenacin succinate tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:48f82298-6600-4c69-a638-8dae15083fd9 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption After oral administration of solifenacin succinate tablets in healthy volunteers, peak plasma concentrations (C max ) of solifenacin were reached within 3 to 8 hours after administration and, at steady-state ranged from 32.3 to 62.9 ng/mL for the 5 and 10 mg solifenacin succinate tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3788df43-42dd-4778-8289-e32b5844358e (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption After oral administration of solifenacin succinate in healthy volunteers, peak plasma concentrations (C max ) of solifenacin were reached within 3 to 8 hours after administration and, at steady-state, ranged from 32.3 to 62.9 ng/mL for the 5 and 10 mg solifenacin succinate tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d96b386-febf-a510-a896-033e832c8f30 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption After oral administration of Solifenacin Succinate Tablets in healthy volunteers, peak plasma concentrations (C max ) of solifenacin were reached within 3 to 8 hours after administration and, at steady-state, ranged from 32.3 to 62.9 ng/mL for the 5 and 10 mg Solifenacin Succinate Tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:02e2aa54-1ed8-445a-a082-ac2c64b339fe (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption After oral administration of solifenacin succinate in healthy volunteers, peak plasma concentrations (C max ) of solifenacin were reached within 3 to 8 hours after administration and, at steady-state, ranged from 32.3 to 62.9 ng/mL for the 5 and 10 mg solifenacin succinate tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e04812c2-2ff7-4dff-9122-518c18f4935e (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption After oral administration of solifenacin succinate in healthy volunteers, peak plasma concentrations (C max ) of solifenacin were reached within 3 to 8 hours after administration and, at steady-state, ranged from 32.3 to 62.9 ng/mL for the 5 and 10 mg solifenacin succinate tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92b37f2d-b1cf-49e6-a13b-0ead92c0604c (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption After oral administration of solifenacin succinate in healthy volunteers, peak plasma concentrations (C max ) of solifenacin were reached within 3 to 8 hours after administration and, at steady-state, ranged from 32.3 to 62.9 ng/mL for the 5 and 10 mg solifenacin succinate tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:663d992d-23cc-4a8e-acd5-a4bea505ba3a (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption After oral administration of solifenacin succinate in healthy volunteers, peak plasma concentrations (C max ) of solifenacin were reached within 3 to 8 hours after administration and, at steady-state, ranged from 32.3 to 62.9 ng/mL for the 5 and 10 mg solifenacin succinate tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49346a96-3d96-4702-b96e-94e635510dba (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption After oral administration of solifenacin succinate in healthy volunteers, peak plasma concentrations (C max ) of solifenacin were reached within 3 to 8 hours after administration and, at steady-state, ranged from 32.3 ng/mL to 62.9 ng/mL for the 5 mg and 10 mg solifenacin succinate tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8ab4f222-018f-40fc-a6aa-39dab563a8a0 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
l conclusions between the drugs or the dose levels. 12.3 Pharmacokinetics Absorption After oral administration of solifenacin succinate in healthy volunteers, peak plasma concentrations (Cmax) of solifenacin were reached within 3 to 8 hours after administration and, at steady-state, ranged from 32.3 to 62.9 ng/mL for the 5 and 10 mg solifenacin succinate tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51ff19b4-09ac-4796-8869-671ddd62c578 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
l conclusions between the drugs or the dose levels. 12.3 Pharmacokinetics Absorption After oral administration of solifenacin succinate in healthy volunteers, peak plasma concentrations (Cmax) of solifenacin were reached within 3 to 8 hours after administration and, at steady-state, ranged from 32.3 to 62.9 ng/mL for the 5 and 10 mg solifenacin succinate tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b20003a6-f781-4563-9824-3e8b97c763c6 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption After oral administration of solifenacin succinate in healthy volunteers, peak plasma concentrations (C max ) of solifenacin were reached within 3 to 8 hours after administration and, at steady-state, ranged from 32.3 to 62.9 ng/mL for the 5 and 10 mg solifenacin succinate tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c84682ca-afca-a066-e053-2995a90a3257 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption After oral administration of solifenacin succinate in healthy volunteers, peak plasma concentrations (C max ) of solifenacin were reached within 3 to 8 hours after administration and, at steady-state, ranged from 32.3 ng/mL to 62.9 ng/mL for the 5 mg and 10 mg solifenacin succinate tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:010c0657-c907-477f-8bd7-5d455a5f50eb (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption After oral administration of solifenacin succinate in healthy volunteers, peak plasma concentrations (C max ) of solifenacin were reached within 3 to 8 hours after administration and, at steady-state, ranged from 32.3 to 62.9 ng/mL for the 5 and 10 mg solifenacin succinate tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d6525817-bea1-4a4c-bed4-4873ee202cc8 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption After oral administration of Solifenacin Succinate Tablets in healthy volunteers, peak plasma concentrations (C max ) of solifenacin were reached within 3 to 8 hours after administration and, at steady-state, ranged from 32.3 to 62.9 ng/mL for the 5 and 10 mg Solifenacin Succinate Tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d65dcb9-aa67-4cfb-9d15-43d0de327bd7 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption After oral administration of solifenacin succinate in healthy volunteers, peak plasma concentrations (C max ) of solifenacin were reached within 3 to 8 hours after administration and, at steady-state, ranged from 32.3 to 62.9 ng/mL for the 5 and 10 mg solifenacin succinate tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2462e9a4-66a7-4340-9a81-617f3417b495 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption After oral administration of solifenacin succinate in healthy volunteers, peak plasma concentrations (C max ) of solifenacin were reached within 3 to 8 hours after administration and, at steady-state, ranged from 32.3 to 62.9 ng/mL for the 5 and 10 mg solifenacin succinate tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d8e8f6f-0a59-479f-8415-c5c5f19e1977 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
l conclusions between the drugs or the dose levels. 12.3 Pharmacokinetics Absorption After oral administration of solifenacin succinate in healthy volunteers, peak plasma concentrations (Cmax) of solifenacin were reached within 3 to 8 hours after administration and, at steady-state, ranged from 32.3 to 62.9 ng/mL for the 5 and 10 mg solifenacin succinate tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d155c739-6870-4938-ba91-8c1b4b90afe4 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption After oral administration of Solifenacin Succinate Tablets in healthy volunteers, peak plasma concentrations levels (C max ) of solifenacin were reached within 3 to 8 hours after administration and, at steady-state, ranged from 32.3 to 62.9 ng/mL for the 5 and 10 mg Solifenacin Succinate Tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:97d8a21e-4618-460f-8cf5-97a9d946039e (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption After oral administration of solifenacin succinate in healthy volunteers, peak plasma concentrations (C max ) of solifenacin were reached within 3 to 8 hours after administration and, at steady-state, ranged from 32.3 to 62.9 ng/mL for the 5 and 10 mg solifenacin succinate tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2dfc5d69-8f35-4f57-90b7-46a5f0f0febe (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption After oral administration of solifenacin succinate in healthy volunteers, peak plasma concentrations (C max ) of solifenacin were reached within 3 to 8 hours after administration and, at steady-state, ranged from 32.3 to 62.9 ng/mL for the 5 and 10 mg solifenacin succinate tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fbd6e753-1ed2-418a-8667-c674b215eabb (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption After oral administration of solifenacin succinate tablet in healthy volunteers, peak plasma concentrations (Cmax) of solifenacin were reached within 3 to 8 hours after administration and, at steady-state, ranged from 32.3 to 62.9 ng/mL for the 5 and 10 mg solifenacin succinate tablet tablets, respectively.
3 hours
- Numeric value
- 3
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9558ed7a-e942-4261-8aea-6033352f79b8 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption After oral administration of solifenacin succinate tablets in healthy volunteers, peak plasma concentrations (C max ) of solifenacin were reached within 3 hours to 8 hours after administration and, at steady-state, ranged from 32.3 ng/mL to 62.9 ng/mL for the 5 mg and 10 mg solifenacin succinate tablets, respectively.
Projected row 1416
- Medicine slug
- solifenacin
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 34
- Source count
- 34
- Agreement rate
- 1
- Recorded readings
600 L
- Numeric value
- 600
- Unit
- L
- Source records
- 34
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 34 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9558ed7a-e942-4261-8aea-6033352f79b8 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Solifenacin is highly distributed to non-CNS tissues, having a mean steady-state volume of distribution of 600 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7eb1a5d6-4972-44f4-8ab9-80b932bf81e0 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Solifenacin is highly distributed to non-CNS tissues, having a mean steady-state volume of distribution of 600 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:98b99a4c-201d-46ee-b78c-7634a64d3a8d (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Solifenacin is highly distributed to non-CNS tissues, having a mean steady-state volume of distribution of 600 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:70fece2c-a59f-43f9-abbf-ac67500e90bb (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Solifenacin is highly distributed to non-CNS tissues, having a mean steady-state volume of distribution of 600 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dadb9462-953e-4319-b9f8-5b7255d1cf9c (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Solifenacin is highly distributed to non-CNS tissues, having a mean steady-state volume of distribution of 600 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f0b8f111-1d76-4b04-9e2f-9fca9e5a0b00 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Solifenacin is highly distributed to non-CNS tissues, having a mean steady-state volume of distribution of 600 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9acee910-cdb2-4052-b8b3-c26aff1c8716 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Solifenacin is highly distributed to non-CNS tissues, having a mean steady-state volume of distribution of 600 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56026679-4002-a6c6-e063-6294a90a7b55 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Solifenacin is highly distributed to non-CNS tissues, having a mean steady-state volume of distribution of 600 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a6f154d9-7463-4b80-b80e-c06a06e36141 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Solifenacin is highly distributed to non-CNS tissues, having a mean steady-state volume of distribution of 600 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6479d24f-373e-4c9e-abaf-349f90a2bbb1 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Solifenacin is highly distributed to non-CNS tissues, having a mean steady-state volume of distribution of 600 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:48f82298-6600-4c69-a638-8dae15083fd9 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Solifenacin is highly distributed to non-CNS tissues, having a mean steady-state volume of distribution of 600L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3788df43-42dd-4778-8289-e32b5844358e (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Solifenacin is highly distributed to non-CNS tissues, having a mean steady-state volume of distribution of 600 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d96b386-febf-a510-a896-033e832c8f30 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Solifenacin is highly distributed to non-CNS tissues, having a mean steady-state volume of distribution of 600 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b0a0651e-1488-36b7-e053-2995a90a3f14 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Solifenacin is highly distributed to non-CNS tissues, having a mean steady-state volume of distribution of 600L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:02e2aa54-1ed8-445a-a082-ac2c64b339fe (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Solifenacin is highly distributed to non-CNS tissues, having a mean steady-state volume of distribution of 600 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e04812c2-2ff7-4dff-9122-518c18f4935e (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Solifenacin is highly distributed to non-CNS tissues, having a mean steady-state volume of distribution of 600 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aea71cde-6d62-4f8d-b813-47064cb213d9 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Solifenacin is highly distributed to non-CNS tissues, having a mean steady-state volume of distribution of 600L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92b37f2d-b1cf-49e6-a13b-0ead92c0604c (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Solifenacin is highly distributed to non-CNS tissues, having a mean steady-state volume of distribution of 600 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:663d992d-23cc-4a8e-acd5-a4bea505ba3a (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Solifenacin is highly distributed to non-CNS tissues, having a mean steady-state volume of distribution of 600 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49346a96-3d96-4702-b96e-94e635510dba (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Solifenacin is highly distributed to non-CNS tissues, having a mean steady-state volume of distribution of 600 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8ab4f222-018f-40fc-a6aa-39dab563a8a0 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Solifenacin is highly distributed to non-CNS tissues, having a mean steady-state volume of distribution of 600L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51ff19b4-09ac-4796-8869-671ddd62c578 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Solifenacin is highly distributed to non-CNS tissues, having a mean steady-state volume of distribution of 600L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b20003a6-f781-4563-9824-3e8b97c763c6 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Solifenacin is highly distributed to non-CNS tissues, having a mean steady-state volume of distribution of 600 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c84682ca-afca-a066-e053-2995a90a3257 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Solifenacin is highly distributed to non-CNS tissues, having a mean steady-state volume of distribution of 600 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:010c0657-c907-477f-8bd7-5d455a5f50eb (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Solifenacin is highly distributed to non-CNS tissues, having a mean steady-state volume of distribution of 600 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d6525817-bea1-4a4c-bed4-4873ee202cc8 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Solifenacin is highly distributed to non-CNS tissues, having a mean steady-state volume of distribution of 600 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d65dcb9-aa67-4cfb-9d15-43d0de327bd7 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Solifenacin is highly distributed to non-CNS tissues, having a mean steady-state volume of distribution of 600 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2462e9a4-66a7-4340-9a81-617f3417b495 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Solifenacin is highly distributed to non-CNS tissues, having a mean steady-state volume of distribution of 600 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d8e8f6f-0a59-479f-8415-c5c5f19e1977 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Solifenacin is highly distributed to non-CNS tissues, having a mean steady-state volume of distribution of 600L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d155c739-6870-4938-ba91-8c1b4b90afe4 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Solifenacin is highly distributed to non-CNS tissues, having a mean steady-state volume of distribution of 600 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c67107f4-348b-4a23-a67c-26fd8241ebd6 (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Solifenacin is highly distributed to non-CNS tissues, having a mean steady-state volume of distribution of 600 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:97d8a21e-4618-460f-8cf5-97a9d946039e (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Solifenacin is highly distributed to non-CNS tissues, having a mean steady-state volume of distribution of 600 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2dfc5d69-8f35-4f57-90b7-46a5f0f0febe (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Solifenacin is highly distributed to non-CNS tissues, having a mean steady-state volume of distribution of 600 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fbd6e753-1ed2-418a-8667-c674b215eabb (opens source in a new tab)
Solifenacin label
Version not recorded · Effective date not recorded
Solifenacin is highly distributed to non-CNS tissues, having a mean steady-state volume of distribution of 600L.
Projected row 1417
- Medicine slug
- somatropin
- Compared field
- bioavailability
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 6
- Source count
- 3
- Agreement rate
- 0.333333
- Recorded readings
70 to 90%
- Numeric value
- 70
- Unit
- %
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:62b01d29-90f0-45b2-a0c4-3a750ba36c8a (opens source in a new tab)
Somatropin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: The absolute bioavailability after subcutaneous administration was determined to be 70 to 90%.
70%
- Numeric value
- 70
- Unit
- %
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:85ba081b-bee0-4a9a-aa0f-ae5b5e9a0886 (opens source in a new tab)
Somatropin label
Version not recorded · Effective date not recorded
The absolute bioavailability of somatropin is approximately 70% after subcutaneous administration.
75%
- Numeric value
- 75
- Unit
- %
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a774e1ae-3997-49ee-8b0e-99a2b315d409 (opens source in a new tab)
Somatropin label
Version not recorded · Effective date not recorded
The absolute bioavailability of somatropin is 75% after subcutaneous administration.
Projected row 1418
- Medicine slug
- sorafenib
- Compared field
- bioavailability
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 8
- Source count
- 8
- Agreement rate
- 0.875
- Recorded readings
38–49%
- Numeric value
- 38
- Unit
- %
- Source records
- 7
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 7 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:68aa4b7f-3f13-4e73-b572-aa6c11a8429c (opens source in a new tab)
Sorafenib label
Version not recorded · Effective date not recorded
Absorption After administration of sorafenib tablets, the mean relative bioavailability was 38–49% when compared to an oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:93f9c3b2-d4c5-80d3-5421-8b4c29fbf8a6 (opens source in a new tab)
Sorafenib label
Version not recorded · Effective date not recorded
Absorption After administration of sorafenib tablets, the mean relative bioavailability was 38 to 49% when compared to an oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b7919013-1511-44f0-a759-3fa78a9fa178 (opens source in a new tab)
Sorafenib label
Version not recorded · Effective date not recorded
Absorption After administration of sorafenib tablets, the mean relative bioavailability was 38-49% when compared to an oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b5305e23-7bc6-44d8-b177-930c47d1653a (opens source in a new tab)
Sorafenib label
Version not recorded · Effective date not recorded
Absorption After administration of sorafenib tablets tablets, the mean relative bioavailability was 38 to 49% when compared to an oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:faa9d847-2cd5-6538-e053-6394a90aa92b (opens source in a new tab)
Sorafenib label
Version not recorded · Effective date not recorded
Absorption After administration of sorafenib tablets, the mean relative bioavailability was 38–49% when compared to an oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:06f442d6-071e-4081-b7f7-40f3b803ab3f (opens source in a new tab)
Sorafenib label
Version not recorded · Effective date not recorded
Absorption After administration of sorafenib tablets, the mean relative bioavailability was 38–49% when compared to an oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b50667e4-5ebc-4968-a646-d605058dbef0 (opens source in a new tab)
Sorafenib label
Version not recorded · Effective date not recorded
Absorption After administration of NEXAVAR tablets, the mean relative bioavailability was 38–49% when compared to an oral solution.
38%
- Numeric value
- 38
- Unit
- %
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dae598f7-823f-405c-ae31-f924594187b9 (opens source in a new tab)
Sorafenib label
Version not recorded · Effective date not recorded
Absorption After administration of sorafenib tablets, the mean relative bioavailability was 38% to 49% when compared to an oral solution.
Projected row 1419
- Medicine slug
- sorafenib
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 8
- Source count
- 8
- Agreement rate
- 1
- Recorded readings
25 to 48 hours
- Numeric value
- 25
- Unit
- hours
- Source records
- 8
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 8 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:68aa4b7f-3f13-4e73-b572-aa6c11a8429c (opens source in a new tab)
Sorafenib label
Version not recorded · Effective date not recorded
Elimination The mean elimination half-life of sorafenib was approximately 25 to 48 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:93f9c3b2-d4c5-80d3-5421-8b4c29fbf8a6 (opens source in a new tab)
Sorafenib label
Version not recorded · Effective date not recorded
Elimination The mean elimination half-life of sorafenib was approximately 25 to 48 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b7919013-1511-44f0-a759-3fa78a9fa178 (opens source in a new tab)
Sorafenib label
Version not recorded · Effective date not recorded
Elimination The mean elimination half-life of sorafenib was approximately 25 to 48 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b5305e23-7bc6-44d8-b177-930c47d1653a (opens source in a new tab)
Sorafenib label
Version not recorded · Effective date not recorded
Elimination The mean elimination half-life of sorafenib was approximately 25 to 48 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:faa9d847-2cd5-6538-e053-6394a90aa92b (opens source in a new tab)
Sorafenib label
Version not recorded · Effective date not recorded
Elimination The mean elimination half-life of sorafenib was approximately 25 to 48 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dae598f7-823f-405c-ae31-f924594187b9 (opens source in a new tab)
Sorafenib label
Version not recorded · Effective date not recorded
Elimination The mean elimination half-life of sorafenib was approximately 25 to 48 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:06f442d6-071e-4081-b7f7-40f3b803ab3f (opens source in a new tab)
Sorafenib label
Version not recorded · Effective date not recorded
Elimination The mean elimination half-life of sorafenib was approximately 25 to 48 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b50667e4-5ebc-4968-a646-d605058dbef0 (opens source in a new tab)
Sorafenib label
Version not recorded · Effective date not recorded
Elimination The mean elimination half-life of sorafenib was approximately 25 to 48 hours.
Projected row 1420
- Medicine slug
- sotalol
- Compared field
- bioavailability
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 47
- Source count
- 47
- Agreement rate
- 0.978723
- Recorded readings
90 to 100%
- Numeric value
- 90
- Unit
- %
- Source records
- 46
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 46 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6f3145d7-f3c9-4456-a77d-d04c54f24668 (opens source in a new tab)
Sotalol label
Version not recorded · Effective date not recorded
Absorption In healthy subjects, the oral bioavailability of sotalol is 90 to 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a56c82e-7ecd-43b0-2899-f89e47adf7db (opens source in a new tab)
Sotalol label
Version not recorded · Effective date not recorded
Absorption In healthy subjects, the oral bioavailability of sotalol is 90 to 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:866e5717-3de2-4f19-b7c7-2275caeef78b (opens source in a new tab)
Sotalol label
Version not recorded · Effective date not recorded
Absorption In healthy subjects, the oral bioavailability of sotalol is 90 to 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c824f6b2-80c5-45a6-a491-4c14c9f5e33d (opens source in a new tab)
Sotalol label
Version not recorded · Effective date not recorded
Absorption In healthy subjects, the oral bioavailability of sotalol is 90–100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56326224-fc80-4b89-8ba3-70cb873173b4 (opens source in a new tab)
Sotalol label
Version not recorded · Effective date not recorded
Absorption In healthy subjects, the oral bioavailability of sotalol is 90 to 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51cebe16-4496-4f49-b2db-b7b21c08fa23 (opens source in a new tab)
Sotalol label
Version not recorded · Effective date not recorded
Absorption In healthy subjects, the oral bioavailability of sotalol is 90–100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56dd490f-4d78-447c-a460-f55587e8a764 (opens source in a new tab)
Sotalol label
Version not recorded · Effective date not recorded
Absorption In healthy subjects, the oral bioavailability of sotalol is 90 to 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6674d53a-7137-4822-8841-4982f702a1b8 (opens source in a new tab)
Sotalol label
Version not recorded · Effective date not recorded
Absorption In healthy subjects, the oral bioavailability of sotalol is 90 to 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8e2772cb-7dea-42d1-ba31-d479ba7cb09a (opens source in a new tab)
Sotalol label
Version not recorded · Effective date not recorded
Absorption In healthy subjects, the oral bioavailability of sotalol is 90 to 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c8ac6351-b1e9-4dd2-82f2-5980814fda15 (opens source in a new tab)
Sotalol label
Version not recorded · Effective date not recorded
Absorption In healthy subjects, the oral bioavailability of sotalol is 90 to 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a6a7702f-36c9-45db-b640-453dc324baee (opens source in a new tab)
Sotalol label
Version not recorded · Effective date not recorded
Absorption In healthy subjects, the oral bioavailability of sotalol is 90 to 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe82c866-03d4-e07b-e053-6394a90a8b1e (opens source in a new tab)
Sotalol label
Version not recorded · Effective date not recorded
Absorption In healthy subjects, the oral bioavailability of sotalol is 90 to 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:27c73b70-99e8-40e8-8aa9-36d3addd3bb4 (opens source in a new tab)
Sotalol label
Version not recorded · Effective date not recorded
Absorption In healthy subjects, the oral bioavailability of sotalol is 90 to 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:253da1e1-022a-4175-bd7f-e7673cba0767 (opens source in a new tab)
Sotalol label
Version not recorded · Effective date not recorded
Absorption In healthy subjects, the oral bioavailability of sotalol is 90–100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f8d0daf3-5eab-44f1-9dec-40e5d9c2bbcf (opens source in a new tab)
Sotalol label
Version not recorded · Effective date not recorded
Absorption In healthy subjects, the oral bioavailability of sotalol is 90 to 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6acf10b5-bbd9-4993-99a9-2cdb8cec96c5 (opens source in a new tab)
Sotalol label
Version not recorded · Effective date not recorded
Absorption In healthy subjects, the oral bioavailability of sotalol is 90 to 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44d0ce4c-de00-4151-ad7f-48a59040a9b0 (opens source in a new tab)
Sotalol label
Version not recorded · Effective date not recorded
Absorption In healthy subjects, the oral bioavailability of sotalol is 90 to 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:667fc1f2-6ccf-4373-89d8-6a064ee7509e (opens source in a new tab)
Sotalol label
Version not recorded · Effective date not recorded
Absorption In healthy subjects, the oral bioavailability of sotalol is 90 to 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9a36d95c-6e93-4e57-befe-b5274f359244 (opens source in a new tab)
Sotalol label
Version not recorded · Effective date not recorded
Absorption In healthy subjects, the oral bioavailability of sotalol is 90 to 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b534c632-3b67-4812-a045-3e582eda6de4 (opens source in a new tab)
Sotalol label
Version not recorded · Effective date not recorded
Absorption In healthy subjects, the oral bioavailability of sotalol is 90 to 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56879738-8662-4f5c-8386-761ab2b5e46f (opens source in a new tab)
Sotalol label
Version not recorded · Effective date not recorded
Absorption In healthy subjects, the oral bioavailability of sotalol is 90–100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:89b33c45-ece8-496f-9c3a-94ebabf73b1b (opens source in a new tab)
Sotalol label
Version not recorded · Effective date not recorded
Absorption In healthy subjects, the oral bioavailability of sotalol is 90 to 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7cb4879f-31e7-4862-bc0c-d439e592d81c (opens source in a new tab)
Sotalol label
Version not recorded · Effective date not recorded
Absorption In healthy subjects, the oral bioavailability of sotalol is 90 to 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:517824b1-11be-40a9-9066-d1a6a32a2938 (opens source in a new tab)
Sotalol label
Version not recorded · Effective date not recorded
Pharmacokinetics In healthy subjects, the oral bioavailability of sotalol hydrochloride is 90 to 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bc35a3e8-681c-4fe8-96cd-b2a62f024c4b (opens source in a new tab)
Sotalol label
Version not recorded · Effective date not recorded
Absorption In healthy subjects, the oral bioavailability of sotalol is 90 to 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d6c8f659-1c32-4431-bdb2-3211a1c81006 (opens source in a new tab)
Sotalol label
Version not recorded · Effective date not recorded
Absorption In healthy subjects, the oral bioavailability of sotalol is 90 to 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10b7b81d-9ce7-4025-8559-fdfa41c8b146 (opens source in a new tab)
Sotalol label
Version not recorded · Effective date not recorded
Absorption In healthy subjects, the oral bioavailability of sotalol is 90 to 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4614480b-b36e-4dbd-9fc0-d083890d297d (opens source in a new tab)
Sotalol label
Version not recorded · Effective date not recorded
Absorption In healthy subjects, the oral bioavailability of sotalol is 90 to 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5ede17b7-3898-4f9f-abec-e15620cef76a (opens source in a new tab)
Sotalol label
Version not recorded · Effective date not recorded
Pharmacokinetics In healthy subjects, the oral bioavailability of sotalol is 90 to 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2f13a6dd-dd77-47c8-ac5d-4a746c32dbd0 (opens source in a new tab)
Sotalol label
Version not recorded · Effective date not recorded
Absorption In healthy subjects, the oral bioavailability of sotalol is 90 to 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1f2ee505-eb90-885d-e063-6394a90a46a1 (opens source in a new tab)
Sotalol label
Version not recorded · Effective date not recorded
Absorption In healthy subjects, the oral bioavailability of sotalol is 90 to 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:282b48b2-f9ff-474a-b01e-68a9ce5edf07 (opens source in a new tab)
Sotalol label
Version not recorded · Effective date not recorded
Absorption In healthy subjects, the oral bioavailability of sotalol is 90–100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0fd4afc7-dbf8-46be-9657-aa83bbb2c026 (opens source in a new tab)
Sotalol label
Version not recorded · Effective date not recorded
Absorption In healthy subjects, the oral bioavailability of sotalol is 90 to 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f5902e1-9f9f-4c6b-817d-2efbb5e28061 (opens source in a new tab)
Sotalol label
Version not recorded · Effective date not recorded
Absorption In healthy subjects, the oral bioavailability of sotalol is 90 to 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:14ee4756-52f2-4bbf-bd79-663839ecb1c5 (opens source in a new tab)
Sotalol label
Version not recorded · Effective date not recorded
Absorption In healthy subjects, the oral bioavailability of sotalol is 90 to 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e6ea445d-4d7c-4c32-83a7-e7683a56075b (opens source in a new tab)
Sotalol label
Version not recorded · Effective date not recorded
Absorption In healthy subjects, the oral bioavailability of sotalol is 90 to 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5e005309-4eca-4536-8743-c6ed9e5b3195 (opens source in a new tab)
Sotalol label
Version not recorded · Effective date not recorded
Absorption In healthy subjects, the oral bioavailability of sotalol is 90 to 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6be8c8f2-3977-4b7f-ad45-38b3254afdab (opens source in a new tab)
Sotalol label
Version not recorded · Effective date not recorded
Absorption In healthy subjects, the oral bioavailability of sotalol is 90 to 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:876214ba-59c4-4acc-a8ad-c6bc91837de8 (opens source in a new tab)
Sotalol label
Version not recorded · Effective date not recorded
Absorption In healthy subjects, the oral bioavailability of sotalol is 90 to 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db9b0b36-4c00-45b6-a50a-e08d7c61a17c (opens source in a new tab)
Sotalol label
Version not recorded · Effective date not recorded
Absorption In healthy subjects, the oral bioavailability of sotalol is 90 to 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5962c4ee-c8f7-4e38-ab8c-4848c7644362 (opens source in a new tab)
Sotalol label
Version not recorded · Effective date not recorded
Absorption In healthy subjects, the oral bioavailability of sotalol is 90–100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:31404462-7fa0-20d6-e063-6294a90aa58c (opens source in a new tab)
Sotalol label
Version not recorded · Effective date not recorded
Absorption In healthy subjects, the oral bioavailability of sotalol is 90 to 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1f33f900-0777-4a92-a7f7-00cf3d57d95c (opens source in a new tab)
Sotalol label
Version not recorded · Effective date not recorded
Absorption In healthy subjects, the oral bioavailability of sotalol is 90 to100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bbeaba9f-0513-4980-bc29-7f9259a53ecc (opens source in a new tab)
Sotalol label
Version not recorded · Effective date not recorded
Absorption In healthy subjects, the oral bioavailability of sotalol is 90 to 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c0a34c56-9641-4592-9754-bcc233ec86b6 (opens source in a new tab)
Sotalol label
Version not recorded · Effective date not recorded
Absorption In healthy subjects, the oral bioavailability of sotalol is 90 to 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bcbc1624-283e-732f-e053-2995a90a8f11 (opens source in a new tab)
Sotalol label
Version not recorded · Effective date not recorded
Absorption In healthy subjects, the oral bioavailability of sotalol is 90 to 100%.
90%
- Numeric value
- 90
- Unit
- %
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff3061ab-d930-4318-a5be-684e38be229e (opens source in a new tab)
Sotalol label
Version not recorded · Effective date not recorded
Absorption In healthy subjects, the oral bioavailability of sotalol is >90%.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=1410Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.